Deals Shaping the Medical Industry (1/07)
Executive Summary
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A
Shire's cash-strapped partner Xenetic, whose technology enabled the long-acting Factor VIII, said on May 22 that SHP656 could not achieve once-weekly dosing in a Phase I/II clinical trial. The market for such a product may be limited anyway given current competition and payer preferences.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.
To Prevent Shortages, US FDA Wants Sponsor To Provide Notifications Of Demand Spike
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.